Arcutis Biotherapeutics Inc. Company Profile
NASDAQ: ARQTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 12:19 PM ET
Arcutis Biotherapeutics at a glance
Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Westlake Village, CA. Arcutis Biotherapeutics is led by Mr. Todd Franklin Watanabe M.A. and employs about 354 people. The company's shares have traded publicly since 2020.
At a market capitalization of $3.01 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001787306, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Arcutis Biotherapeutics do?
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Business description based on the company's public filings.
Company information
- Legal name
- Arcutis Biotherapeutics Inc.
- Ticker
- NASDAQ: ARQT
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Todd Franklin Watanabe M.A.
- Employees
- 354
- Headquarters
- 3027 Townsgate Road, Westlake Village, CA, United States
- Phone
- 805 418 5006
- Website
- arcutis.com
- IPO year
- 2020
- Market cap
- $3.01B
- SEC CIK
- 0001787306
Companies similar to Arcutis Biotherapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DYNDyne Therapeutics Inc. | 15.87 | -0.63% | $2.96B | vs ARQT |
| RCUSArcus Biosciences Inc. | 22.95 | -6.40% | $2.89B | vs ARQT |
| ELVNEnliven Therapeutics Inc. | 39.36 | -4.84% | $2.88B | vs ARQT |
| PBLSParabilis Medicines Inc. | 26.51 | -8.02% | $3.27B | vs ARQT |
| AMLXAmylyx Pharmaceuticals Inc. | 26.40 | -3.75% | $3.31B | vs ARQT |
| ZLABZai Lab Limited ADR | 23.94 | -5.41% | $2.69B | vs ARQT |
| PGENPrecigen Inc. | 7.49 | -0.73% | $2.68B | vs ARQT |
| ACADACADIA Pharmaceuticals Inc. | 19.37 | -1.42% | $3.34B | vs ARQT |